Clinical Research Facility

Hixson, Tennessee 37343

We've found

1 trials

at this facility

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Hixson, TN

Use our guide to learn which trials are right for you!